Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2019

View Archived Issues

Inhibition of cystine/glutamate antiporter system Xc- identified as a possible target for epilepsy

Risk assessment for long QT syndrome

Mapping microbial metabolites to GPCRs

Phase II data for unadjuvanted subvirion monovalent inactivated influenza H3N2v vaccine

Syros Pharmaceuticals presents new CDK7/cyclin H inhibitors

Novel M4 positive allosteric modulator with improved physicochemical properties and favorable PK

Elicio presents preclinical data for ELI-002 vaccine targeting KRAS-driven cancers

APOC1 as a novel diagnostic and prognostic biomarker for gastric cancer

ZL-0580: a novel BRD4-selective small molecule that suppresses HIV

89bio initiates phase Ib/IIa study of BIO89-100 for the treatment of NASH

DPS-2: A dual MEK/ERK and PI3K/AKT inhibitor developed for colorectal cancer

First patient dosed in phase Ib/IIa PREVAIL study of PRV-3279

Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25%

TaiGen Biotechnology presents influenza cap-dependent endonuclease inhibitors

Immuron reports data from TREAT-003 study of IMM-124-E in severe alcoholic hepatitis

New selective estrogen receptor modulators disclosed by Radius Pharmaceuticals

Sesen Bio presents developmental update for Vicinium

NIH awards major grant to ImmunogenX to conduct phase II study for latiglutenase

Hemispherx reports positive safety and survival data from phase I study of Ampligen

New liver cell discovery may enable hepatic regeneration

Starpharma initiates phase I/II study of DEP irinotecan

Phase IIb/III THEIA-1 study of TOP-1630 does not meet primary endpoints

FDA accepts Agenus' AGEN-2373 IND filing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...